Evangelos F.
- Country
- Greece
- Department
- Oncology
Research Overview
- Comparison of Sotorasib Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in PD-L1 Negative KRAS p.G12C Positive Advanced Non-Squamous NSCLC
- Phase 2/3 Study of EIK1001 Combined with Pembrolizumab and Chemotherapy in Stage IV Non-Small Cell Lung Cancer
- Phase 3 Randomized Double‑Blind Study of MK‑1084 + Durvalumab vs Placebo + Durvalumab in Locally Advanced KRAS G12C‑Mutant Unresectable NSCLC Post‑Chemoradiotherapy
Data & Insights
Has run more than one trial at 110 of 329 partner sites.
Specializations
Oncology Focus
This investigator specializes in non-small cell lung cancer (NSCLC) treatment, with particular emphasis on resectable cases at clinical stages II through IIIB.
- Surgical Oncology
- Early-Stage Lung Cancer Management
- Nodal Involvement Assessment
The investigator's work centers on evaluating innovative therapeutic approaches for post-surgical cancer care.
Immunotherapy Research
The investigator focuses on immunotherapy applications in lung cancer treatment, particularly exploring the efficacy of pembrolizumab in various therapeutic combinations.
- Combination Therapy Approaches
- Post-Surgical Treatment Strategies
- Disease-Free Survival Assessment
Their research examines novel therapeutic combinations to enhance treatment outcomes in resectable lung cancer.
Clinical Assessment
The investigator specializes in Blinded Independent Central Review (BICR) methodologies for evaluating treatment effectiveness in oncology.
- Treatment Response Evaluation
- Disease Progression Monitoring
- Clinical Staging Assessment
Their expertise includes systematic evaluation of therapeutic interventions in early-stage lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.